semaglutide and cardiovascular outcomes in patients with type 2 diabetes SELECT Trial 1200.07 Comparison Of the Efficacy

health systems with a medicine that can treat obesity, diabetes, and cardiovascular disease is woefully inadequate

But dozens of studies are researching whether they might have other benefits, too

Relevant Financial Relationships: None

But this also creates a paradox: some companies or providers may see reduced volumes or sales of these high-cost services, posing challenges to traditional healthcare business modelssomething management teams and healthcare investors are watching very closely

published a comprehensive review on the use of GLP-1 RAs in plastic surgery, focusing for the first time primarily on their potential benefits and practical considerations in reconstructive procedures [96]